Amylin’s New Type 2 Diabetes Treatment, Bydureon, Now Available in US Pharmacies

The newly approved type 2 diabetes drug  Bydureon, made by Amylin Pharmaceuticals and Alkermes plc, is now available by prescription in U.S. pharmacies.
Bydureon is the first and only once-weekly treatment for type 2 diabetes.  It was approved by the US FDA on January 27th 2012 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The approval was based on safety and efficacy data from the DURATION clinical trial program, in which treatment with  Bydureon  resulted in improvements in glycemic control in a once-weekly dose. 
Bydureon is provided in a straightforward single-dose tray so that patients can self-administer the once-weekly subcutaneous injection. To help patients get off to a successful start, Amylin offers Bydureon  Steady Support for patients and healthcare providers.  Bydureon Steady Support offerings include flexible resources for healthcare providers and their patients to learn about  Bydureon, how to administer it and how to sign up to receive ongoing support to help manage type 2 diabetes. This support will include access to  Bydureon specialists seven days a week via a toll-free number, interactive tutorials online and the opportunity to schedule in-person training sessions with a diabetes educator. 
Amylin says it is committed to assisting patients with diabetes in accessing coverage for  Bydureon. Eligible patients will have access to the  Bydureon Steady Savings Card to help offset copay costs. With the Steady Savings Card, these patients can save up to $50 per month on Bydureon prescriptions for up to 24 months. A patient assistance program is also available for eligible patients who have been prescribed  Bydureon but do not have insurance for prescription drugs. Additional information can be found at
Author image
ASweetLife Team

Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x